For the treatment of canine misalliance
Aglepristone is a synthetic progesterone antagonist, effective on uterine progesterone receptors, with a relative binding affinity three times stronger than endogenous progesterone, providing effective competitive antagonism of progesterone and blocking the hormone responsible for implantation and pregnancy maintenance
Product Features & Benefits:
High efficacy over a flexible treatment period from 0 to 45 days post-mating
Two doses 24 hours apart (timing is important in its success)
Given by subcutaneous injection, at 1ml / 3kg, using a maximum of 5ml per injection site
Excellent safety profile
Use medicines responsibly. www.noah.co.uk/responsible.
Further information is available on the SPC or on request from Virbac Ltd.
Canine Castration: Is There More Than One Way To Crack A Nut?
Along with positive socialisation, training and appropriate nutrition, castration is often considered a key component of responsible dog ownership. As well as preventing accidental mating, castration can be beneficial in preventing specific testosterone related disease and can help in the management of some behavioural issues.
Alizin contains Aglepristone, a progesterone receptor antagonist that blocks the hormone needed for implantation and placental development, causing abortion within a few days of the course.
Alizin is authorised to induce abortion from day 1 to 45 post mating although we recommend waiting to the end of oestrus before using the product to avoid the need for repeat courses. This is usually 10 to 14 days post mating.
In the first trimester (up to day 21) the efficacy is 99.9%. In the second trimester the aglepristone acts on placental development and efficacy is 95%.
The dose is 10mg/kg and the concentration of the vial is 30mg per ml.
The abortion process will start within a few days and be completed by 7 days.
In case of partial abortion or no abortion, repeat treatment may be recommended 10 days after treatment, between day 30 and day 45 after mating. Surgery should also be considered.
There is no evidence that aglepristone causes mutations or congenital abnormalities.